Similarly, a model established using m5C-related genes can also evaluate prognosis and immune therapy efficacy, with liver and pancreatic cancers with lower m5C scores being more sensitive to anti-CTLA-4 therapy, and pancreatic cancer also being sensitive to anti-PD-1 therapy (166). This evidence concerns the gene CTLA4 and pancreatic neoplasm.